Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

New England Journal of Medicine - United States
doi 10.1056/nejmc1708349
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors

Unknown

Publisher

Massachusetts Medical Society

Related search

Cannabidiol: FDA Approved New Drug for the Lennox-Gastaut Syndrome and Dravet Syndrome: Pharmacotherapeutics Review

NeuroPharmac Journal
2019English

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens

JAMA Neurology
Neurology
2020English

FDA-approves the First Therapy in 2018 for the Seizures Associated With Dravet Syndrome

NeuroPharmac Journal
2019English

Perineal Stimulation Triggering Seizures in a Child With Dravet Syndrome

Seizure : the journal of the British Epilepsy Association
MedicineNeurology
2018English

Stiripentol: New Approved Drug for the Dravet Syndrome: Pharmacotherapeutics Review

NeuroPharmac Journal
2019English

Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening

Frontiers in Pharmacology
Pharmacology
2018English

Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome

eNeuro
MedicineNeuroscience
2015English

A Prospective Open-Label Trial of a CBD/THC Cannabis Oil in Dravet Syndrome

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Drug Screening in Scn1a Zebrafish Mutant Identifies Clemizole as a Potential Dravet Syndrome Treatment

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy